I
n
An amazing place to develop the vaccines of tomorrow GSK is the world’s leading vaccine company, with a portfolio that helps to protect people throughout life, and an innovative pipeline of 15 vaccines in development. We deliver over 2 million vaccine doses per day to people in more than 160 countries. According to the World Health Organization (WHO), only clean water rivals vaccination in its ability to save lives.
G
SK Vaccines has developed vaccines against 21 of the 31 diseases currently preventable by vaccination to help protect people at all stages of their life. Over the last ten years, in Belgium, this division invested €3 billion in infrastructure and capacity building. Furthermore, GSK Vaccines has become the largest pharmaceutical company in Belgium with >9,000 employees. Our vaccine scientists work in three global R&D centers in Rixensart (Belgium), Italy and the US. In 2019, we invested about €1 billion in vaccines R&D.
CureVac make it possible to identify a genetic code of an antigen (the active ingredient of the vaccine), to generate a candidate vaccine more quickly – a revolution for the manufacturing phase.
© GSK Vaccines
GSK Vaccines has defined its R&D key priorities: increasing our portfolio of new vaccines against a respiratory virus (RSV) – a leading cause of bronchiolitis in babies and pneumonia in adults, reducing antibiotic resistance (AMR) through disease prevention, therapeutic vacDr Emmanuel Hanon, cines and personalized vaccines. To achieve Senior Vice President of Vaccine Research GSK Vaccines relies upon partnership and a this goal, GSK Vaccines leverages digitalization, at GSK Vaccines 100-year legacy of vaccine development that artificial intelligence, and machine learning to enabled frontline innovation in areas such as recombinant vaccines, design vaccine antigens and measure their broader benefit to pediatric vaccines, vaccines with new adjuvants, vaccines against society through health data analysis. respiratory and meningococcal diseases, pandemic vaccines, and a vaccine against herpes zoster. Collaborations with external partners (Belgian universities, the NIH in United States, biotech companies, the European Commission through the Innovative Medicines Initiative or IMI) are a core part of the R&D culture.
© GSK Vaccines
In 2020, the year of the COVID-19 pandemic, we are working with others on several COVID-19 vaccine candidates contributing our pandemic adjuvant technology (developed in Rixensart). An adjuvant is added to some vaccines to enhance the immune response, thereby creating a stronger and longer lasting immunity against infections than the vaccine alone. The use of an adjuvant is of particular importance in a pandemic situation since it can reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and made available to more people. Our site in Wavre, Belgium, the largest vaccine manufacturing site worldwide, will also contribute to the manufacturing of up to 1 billion adjuvant doses for our COVID-19 collaborations in 2021.
GSK site in Wavre – largest vaccine manufacturing site worldwide
GSK is currently undergoing a two-year programme to separate into two companies: one leading biopharma company, and another company focusing on consumer healthcare activities. Experts and teams across GSK pharma and vaccines will thus build upon a common approach to R&D in order to deliver transformational vaccines and medicines. Moreover, the Vaccines division is innovating in therapeutic vaccines: next generation of vaccines could play a strong role to slow down or stop disease progression, or even act as a cure for a disease. They could become an important tool in reducing the spread of antibiotic resistance and anti-microbial resistance globally.
© GSK Vaccines
n
o
v
a
t
i
o
n
T e
c
h
n
o
l
o
g
y
GSK
GSK site in Rixensart – historical vaccine Research & Development site
GlaxoSmithKline Vaccines
Additionally, GSK Vaccines strives to significantly accelerate the vaccine development times thanks to potential breakthroughs including mRNA platform technologies. Our self-amplifying RNA (SAM) platform or our collaboration with a global mRNA leader
Avenue Fleming 20 - 1300 Wavre Email: elisabeth.e.vandamme@gsk.com (external communication for GSK in Belgium) https://be.gsk.com 116
